AUTHORS
Rui MA, Yuqian Sun, MD2, Maud Ngoya3, Johanna Tischer4, Renato Fanin5, Hermann Einsele, MD, PhD6, Pavel Jindra, PhD7, Gerald Wulf8, Matthias Stelljes9, Lucia Lopez Corral, MD, PhD10, Elisa Sala, MD, PhD11, Linde Morsink12, Maria Pascual, MD13, Peter Von Dem Borne, MD, PhD14, Dominik Schneidawind, MD, PhD15, Ahmet Elmaagacli16, Grzegorz Helbig17, Raffaella Cerretti, MD18, Anna Grassi, MD19, Juan-Manuel Sancho, MD PhD20, Franca Fagioli21, Cristina Tecchio22, Rodrigo Martino, MD23, Umit Barbaros Ure24, Mohamad Mohty, MD, PhD25, Norbert Claude Gorin, MD, PhD26, Alexandros Spyridonidis27, Francesco Saraceni, MD28, Frederic Baron29, Jaime Sanz, MD, PhD30, Xiaojun Huang, MD,PhD31, Arnon Nagler I, MD32, Eolia Brissot, MD, PhD33
AFFILIATIONS
1 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
2 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
3 EBMT Paris Study Unit, Hôpital Saint-Antoine, Paris, France
4 Klinikum Grosshadern, University of Munich, Munich, Germany
5 Azienda Sanitaria Universitaria Friuli Centrale, Udine, Italy
6 Universitaetsklinikum Wuerzburg, Würzburg, Germany
7 Charles University Hospital, Pilsen, Czech Republic
8 Universitaetsklinikum Goettingen, Göttingen, Germany
9 University of Muenster, Münster, Germany
10 Hospital Clinico de Salamanca, Salamanca, Spain
11 Klinik fuer Innere Medizin III, University of Ulm, Ulm, Germany
12 University Medical Center Groningen (UMCG), Groningen, Netherlands
13 Hospital Regional de Malaga, Malaga, Spain
14 Leiden University Hospital, Leiden, Netherlands
15 University Hospital Zurich, Zurich, Switzerland
16 Asklepios Klinik St. Georg, Hamburg, Germany
17 Silesian Medical Academy, Katowice, Poland
18 Tor Vergata University of Rome, Rome, Italy
19 ASST Papa Giovanni XXIII, Bergamo, Italy
20 ICO-Hospital Universitari Germans Trias i Pujol, Badalona, Spain
21 Ospedale Infantile Regina Margherita, Turin, Italy
22 Azienda Ospedaliera Universitaria Integrata Verona, Verona, Italy
23 Hospital Santa Creu i Sant Pau, Barcelona, Spain
24 Koc University Hospital, Istanbul, Turkey
25 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
26 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
27 Bone Marrow Transplantation Unit and Institute of Cell Therapy, University of Patras, Rio, Greece
28 Ematologia, Trapianto e Terapia Cellulare, Azienda Ospedaliero-Universitaria delle Marche, Ancona, Italy
29 University of Liege, Liege, Belgium
30 Hospital Universitari i Politècnic La Fe, Departament de Medicina Universitat de Valencia, Valencia, Spain
31 Peking University People's Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematological Disease, BEIJING, China
32 Division of Hematology, Sheba Medical Center, Tel Hashomer, Israel
33 Department of Hematology and Cell Therapy, Hospital Saint-Antoine, Sorbonne University, Paris, France
ABSTRACT
Background Allogeneic hematopoietic cell transplantation (allo-HCT) is a curative option for older patients with acute myeloid leukemia (AML), but the optimal conditioning intensity remains controversial. Reduced-intensity conditioning (RIC) lowers early non-relapse mortality (NRM) and organ toxicity, enabling HCT in older, comorbid patients but may increase relapse. Conversely, myeloablative conditioning (MAC) offers superior disease control but has historically carried higher NRM. For patients aged 60-70 years with an HCT-specific comorbidity index (HCT-CI) of 0, MAC might be tolerable and improve survival by reducing relapse without excessive NRM, but direct comparisons in this population in first complete remission (CR1) are limited. Therefore, we conducted a retrospective study to evaluate conditioning intensity in this well-defined cohort.
Methods Patients aged 60-70 years with AML in CR1 and HCT-CI=0 receiving first allo-HCT between 2013 and 2024 were identified from the EBMT registry. The primary endpoint was overall survival (OS). Secondary endpoints included engraftment, NRM, relapse, grade II-IV acute GVHD (aGVHD), extensive chronic GVHD (cGVHD), leukemia-free survival (LFS), and GVHD-free/relapse-free survival (GRFS). Kaplan-Meier method was applied for OS and LFS, and cumulative incidence with competing risks was used for relapse, NRM, engraftment, and GVHD. Multivariable analysis, adjusting for potential confounding factors, was performed using Cox regression models for the main transplant outcomes.
Results A total of 501 patients were included (MAC, n=146; RIC, n=355), with a median age of 64.4 years (range 60-70). Donors (MAC vs RIC) were matched sibling (25.3% vs 35.8%), matched unrelated (47.3% vs 42.3%), mismatched unrelated (13.7% vs 10.4%), and haploidentical (13.7% vs 11.5%). Cytogenetics data were available for 174 patients (34.7%), with adverse risk in 25.9%, intermediate in 72.4%, and favorable in 1.7% of patients. MAC recipients were younger (median 63.8 vs 64.5 years, p=0.0012), had younger donors (32.3 vs 39.4 years, p=0.0044), were more often male (63.0% vs 51.8%, p=0.0222), and had more PTCy (22.6% vs 10.1%, p=0.0002), ATG (54.8% vs 42.8%, p=0.0146), and bone marrow grafts (14.4% vs 6.5%, p=0.0045). The most common regimens were BuFlu (52.8%), BuCy (11.8%), and BuCyFlu (11.8%) with MAC, and BuFlu (53.3%), FluMel (21.2%), and FluTreo (9.2%) with RIC. With a median follow-up of 4.3 years, 2-year OS was numerically higher after MAC than after RIC (55.0% vs 48.2%), but without statistical significance in multivariable analysis (RIC vs MAC, HR 1.07, 95% CI 0.77-1.50, p=0.69). Two-year LFS was also numerically higher after MAC (50.6% vs 42.2%) without statistical significance (RIC vs MAC, HR 1.14, 95% CI 0.83-1.56, p=0.42). Neutrophil recovery by day 30 was 92.1% with MAC vs 95.3% with RIC, and platelet recovery by day 60 was 91.4% vs 86.7%. Day-100 grade II-IV aGVHD was comparable (21.6% vs 26.5%, p=0.20). RIC was associated with a higher risk of overall cGVHD (RIC vs MAC, HR 2.14, 95% CI 1.12-4.12, p=0.02), whereas the risk of extensive cGVHD did not differ (RIC vs MAC, HR 1.59, 95% CI 0.54-4.66, p=0.40). Two-year relapse, NRM, and GRFS were comparable (relapse: 29.6% vs 32.9%, p=0.31; NRM: 19.8% vs 24.9%, p=0.49; GRFS: 37.1% vs 32.8%, p=0.27). Among 267 documented deaths (67 in MAC, 200 in RIC), primary disease was the leading cause, accounting for 46.8% of deaths in the MAC group and 47.9% in RIC, followed by treatment-related causes, accounting for 45.2% and 39.9%. In the entire cohort, KPS ≥90 was associated with improved LFS (KPS ≥90 vs <90, HR 0.73, 95% CI 0.55-0.98, p=0.04) and showed a numerically better OS (KPS ≥90 vs <90, HR 0.73, 95% CI 0.54-1.00, p=0.054).
Conclusions In this retrospective EBMT cohort of patients aged 60–70 years with AML in CR1 and HCT-CI=0, no statistically significant differences were detected between MAC and RIC in adjusted OS, LFS, relapse, NRM, grade II-IV aGVHD, or GRFS. Two-year OS and LFS were numerically higher after MAC. Overall cGVHD was more frequent after RIC, whereas extensive cGVHD did not differ significantly. These findings do not establish the superiority of either conditioning strategy and should be interpreted in light of treatment-selection bias and limited disease-risk data. Conditioning intensity should therefore be individualized according to disease risk, functional status, donor characteristics, and institutional experience.
DISCLOSURES
Rui MA: No relevant conflicts of interest to declare.